Tenax Therapeutics, Inc. (NASDAQ:TENX) Stock Has Consensus Price Target of $14.00

Tenax Therapeutics, Inc. (NASDAQ:TENX) has received a consensus rating of “Hold” from the ten brokerages that are currently covering the stock, MarketBeat.com reports. One investment analyst has rated the stock with a sell recommendation, five have assigned a hold recommendation, three have given a buy recommendation and one has issued a strong buy recommendation on the company. The average 12 month price target among analysts that have issued a report on the stock in the last year is $14.00.

Several equities research analysts have commented on TENX shares. Evercore lowered shares of Tenax Therapeutics from an “outperform” rating to an “in-line” rating and set a $5.00 target price on the stock. in a research report on Tuesday, August 11th. Cantor Fitzgerald reiterated an “overweight” rating on shares of Tenax Therapeutics in a report on Thursday, September 10th. Weiss Ratings cut shares of Tenax Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Monday, September 14th. Wall Street Zen downgraded shares of Tenax Therapeutics from a “sell” rating to a “strong sell” rating in a report on Saturday, August 15th. Finally, Leerink Partners set a $4.00 target price on shares of Tenax Therapeutics in a research report on Tuesday, August 11th.

Insider Buying and Selling

In other news, Director Declan Doogan purchased 53,000 shares of the stock in a transaction that occurred on Wednesday, September 16th. The shares were acquired at an average price of $1.92 per share, for a total transaction of $101,760.00. Following the acquisition, the director directly owned 55,274 shares in the company, valued at approximately $106,126.08. The trade was a 2,330.69% increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, major shareholder Adar1 Capital Management, Llc acquired 331,979 shares of the company’s stock in a transaction that occurred on Wednesday, October 21st. The stock was purchased at an average cost of $1.66 per share, with a total value of $551,085.14. Following the completion of the purchase, the insider directly owned 7,447,000 shares in the company, valued at $12,362,020. This represents a 4.67% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. Over the last quarter, insiders have bought 3,682,899 shares of company stock valued at $6,388,279. Insiders own 10.81% of the company’s stock.

Institutional Trading of Tenax Therapeutics

Institutional investors have recently bought and sold shares of the company. Braidwell LP purchased a new stake in shares of Tenax Therapeutics in the 2nd quarter worth about $8,503,000. Janus Henderson Group PLC grew its stake in Tenax Therapeutics by 989.3% in the 1st quarter. Janus Henderson Group PLC now owns 1,815,474 shares of the specialty pharmaceutical company’s stock valued at $29,066,000 after acquiring an additional 1,648,808 shares during the last quarter. ADAR1 Capital Management LLC increased its holdings in Tenax Therapeutics by 235.2% during the 1st quarter. ADAR1 Capital Management LLC now owns 213,462 shares of the specialty pharmaceutical company’s stock valued at $3,413,000 after acquiring an additional 149,789 shares in the last quarter. Avidity Partners Management LP purchased a new position in Tenax Therapeutics during the 1st quarter valued at about $3,453,000. Finally, Perceptive Advisors LLC raised its position in Tenax Therapeutics by 229.7% during the first quarter. Perceptive Advisors LLC now owns 1,447,782 shares of the specialty pharmaceutical company’s stock worth $23,150,000 after acquiring an additional 1,008,640 shares during the last quarter. 1.67% of the stock is currently owned by hedge funds and other institutional investors.

Tenax Therapeutics Price Performance

Tenax Therapeutics stock opened at $1.79 on Friday. The stock has a market capitalization of $66.98 million, a PE ratio of -1.21 and a beta of 0.92. Tenax Therapeutics has a 12 month low of $1.31 and a 12 month high of $19.40. The business has a 50 day simple moving average of $1.84 and a 200-day simple moving average of $10.10.

Tenax Therapeutics (NASDAQ:TENX) last issued its quarterly earnings results on Friday, July 31st. The specialty pharmaceutical company reported ($0.35) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.38) by $0.03. As a group, equities research analysts anticipate that Tenax Therapeutics will post -1.38 EPS for the current year.

Key Stories Impacting Tenax Therapeutics

Here are the key news stories impacting Tenax Therapeutics this week:

• Negative Sentiment: The lawsuit covers investors who purchased Tenax securities from November 13, 2023, through August 7, 2026. The case was filed in federal court and alleges potential violations of U.S. securities laws; the allegations have not been proven. Pomerantz class-action announcement
• Negative Sentiment: The legal claims appear linked to company disclosures concerning TNX-103 and the Phase 3 LEVEL study, including alleged assurances that the trial was enriched with patients most likely to respond. One law firm is also investigating potential securities fraud related to disclosures made on August 10, 2026. Frank R. Cruz investigation
• Negative Sentiment: A series of notices from Bronstein Gewirtz & Grossman, Berger Montague, Kaplan Fox, Faruqi & Faruqi, Rosen, and other firms is increasing visibility around the litigation and may reinforce investor concerns about potential financial, disclosure, and reputational risks. These announcements largely promote the same filed action rather than documenting separate new lawsuits. Bronstein Gewirtz & Grossman announcement
• Neutral Sentiment: Investors who seek to become lead plaintiff must generally apply by December 28, 2026. The deadline itself does not establish liability or guarantee recovery, but it signals that the legal process is moving forward. Berger Montague class-action notice

About Tenax Therapeutics

Tenax Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing therapies for cardiovascular and pulmonary diseases. The company’s research programs are aimed at addressing conditions with significant unmet medical needs, including pulmonary hypertension associated with heart failure with preserved ejection fraction (PH-HFpEF).

Tenax’s lead product candidate is TNX-103, an oral formulation of levosimendan. Levosimendan is a calcium sensitizer and potassium-channel activator that has been approved for certain heart-failure indications outside the United States.